Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Probability of Starting Two-Drug Regimen (2DR) vs. Three-Drug Regimen (3DR) in ART-Naïve and ART-Experienced Person with HIV (PWH) Across the First Wave of COVID-19 Pandemic.
Vergori A, Gianotti N, Tavelli A, Tincati C, Giacomelli A, Matteini E, Lapadula G, Taramasso L, Sarmati L, D'Arminio Monforte A, Antinori A, Cozzi-Lepri A, On Behalf Of The Icona Foundation Study; ICONA Foundation Study. Vergori A, et al. Viruses. 2024 Nov 23;16(12):1822. doi: 10.3390/v16121822. Viruses. 2024. PMID: 39772133 Free PMC article.
Effectiveness and Tolerability of DOR/3TC/TDF in Experienced People with HIV Switching from RPV/FTC/TDF: A Retrospective, Single Center Cohort Study.
Cicalini S, Lanini S, Gagliardini R, Bellagamba R, Vergori A, Mastrorosa I, Mazzotta V, Esvan R, Plazzi MM, Ottou S, Grilli E, De Zottis F, Fusto M, Paulicelli J, Antinori A. Cicalini S, et al. Among authors: vergori a. Pharmaceuticals (Basel). 2024 Dec 17;17(12):1706. doi: 10.3390/ph17121706. Pharmaceuticals (Basel). 2024. PMID: 39770548 Free PMC article.
Impact of switching from EFV/F/TDF to B/F/TAF on psychiatric symptoms and neurocognition.
Vergori A, Del Duca G, Lorenzini P, Brita AC, Mastrorosa I, Fusto M, Camici M, Ottou S, Gagliardini R, Paulicelli J, De Zottis F, Grilli E, Esvan R, Plazzi MM, Mazzotta V, Bellagamba R, Antinori A, Pinnetti C. Vergori A, et al. AIDS. 2024 Oct 25. doi: 10.1097/QAD.0000000000004043. Online ahead of print. AIDS. 2024. PMID: 39453875
Cerebrospinal Fluid and Peripheral Blood Lymphomonocyte Single-Cell Transcriptomics in a Subject with Multiple Sclerosis Acutely Infected with HIV.
Pinnetti C, Rozera G, Messina F, Spezia PG, Lazzari E, Fabeni L, Chillemi G, Pietrucci D, Haggiag S, Mastrorosa I, Vergori A, Girardi E, Antinori A, Maggi F, Abbate I. Pinnetti C, et al. Among authors: vergori a. Int J Mol Sci. 2024 Sep 28;25(19):10459. doi: 10.3390/ijms251910459. Int J Mol Sci. 2024. PMID: 39408789 Free PMC article.
Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves.
Mazzotta V, Mazzaferri F, Lanini S, Mirandola M, Cozzi Lepri A, Vergori A, Savoldi A, Santoro A, Maccarrone G, Mastrorosa I, Simonetti O, Zottis F, Nicastri E, Rosini G, Rovigo L, Tavernaro L, Sarmati L, Tascini C, Girardi E, Cattelan AM, Antinori A, Tacconelli E; MANTICO2/MONET study group. Mazzotta V, et al. Among authors: vergori a. J Infect. 2024 Nov;89(5):106294. doi: 10.1016/j.jinf.2024.106294. Epub 2024 Sep 27. J Infect. 2024. PMID: 39343244 Free article. Clinical Trial.
Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians' and nurses' points of view.
Cingolani A, Tavelli A, De Benedittis S, Mastrorosa I, Muccini C, Bini T, Carraro A, Compagno M, Mazzitelli M, Guastavigna M, Cernuschi M, Torti C, Antinori A, d'Arminio Monforte A; ICONA Foundation Study group. Cingolani A, et al. J Antimicrob Chemother. 2024 Oct 1;79(10):2662-2667. doi: 10.1093/jac/dkae273. J Antimicrob Chemother. 2024. PMID: 39140512
Real World Use of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis of COVID-19 in Immunocompromised Individuals: Data from the OCTOPUS Study.
Vergori A, Matusali G, Cimini E, Bordi L, Borrelli P, Lanini S, Palazzi R, Paulicelli J, Mariotti D, Mazzotta V, Notari S, Casetti R, Francalancia M, Rosati S, D'Abramo A, Mija C, Mencarini P, Milozzi E, Caraffa E, Sica S, Metafuni E, Sorà F, Rago A, Siniscalchi A, Abruzzese E, Garzia M, Luzi G, Battistini R, Prosperini L, Cingolani A, Girardi E, Maggi F, Antinori A; OCTOPUS Study Group. Vergori A, et al. Vaccines (Basel). 2024 Jul 17;12(7):784. doi: 10.3390/vaccines12070784. Vaccines (Basel). 2024. PMID: 39066422 Free PMC article.
HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21.
Fabeni L, Armenia D, Abbate I, Gagliardini R, Mazzotta V, Bertoli A, Gennari W, Forbici F, Berno G, Piermatteo L, Borghi V, Pinnetti C, Vergori A, Mondi A, Parruti G, Di Sora F, Iannetta M, Lichtner M, Latini A, Mussini C, Sarmati L, Perno CF, Girardi E, Antinori A, Ceccherini-Silberstein F, Maggi F, Santoro MM; Italian HIV Drug Resistance Group. Fabeni L, et al. Among authors: vergori a. J Antimicrob Chemother. 2024 Sep 3;79(9):2152-2162. doi: 10.1093/jac/dkae189. J Antimicrob Chemother. 2024. PMID: 39028674 Free PMC article.
127 results